Don’t Miss This: Dreamworks Animation (DWA), Ossen Innovation (OSN), AMAG Pharmaceuticals (AMAG)

Albany, New York (09/30/2014) – Dreamworks Animation Skg Inc (NASDAQ:DWA)’s acquisition talks with SoftBank have reported cooled, according to The Wall Street Journal report citing people with insider knowledge. News about a possible deal between the companies helped shares of DWA up 26% Monday to give it a market cap of over $2 billion on the day. DWA reported a loss of $15.4 million on revenue figure of $122.3 million in its 2Q. Some sources further cited that SoftBank and DWA could still restart their talks, but a different deal other than an outright buyout is likely to emerge.

Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) soared to 55% to $1.38 on the back of encouraging quarterly performance. The $18 million China-based maker of plain surface, zinc and rare earth materials announced results for the three months trading period ended June 30. Revenue for the period was $35.9 million, 49% above the same period a year ago. The increase in revenue was supported by increase in product demand and acquisition of new customers. OSN reported 30% decline in selling expenses, which was due to lower transportation costs. However, general and administrative expenses jumped up 50% to $1.4 million because of the higher Research and Development spending. Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) reported a net income of $1.5 million or $0.07 per share, which was better than $0.7 million or $0.04 per share a year ago.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)’s deal to buy Lumara Health could possibly reach $1 billion. AMAG agreed to buy Lumara for $675 million in a transaction that involves cash and stock. The cash component of the deal is expected to $600 million while $75 million would be paid in stock. AMAG also agreed to pay an additional $350 million in future milestones if certain targets are met. That means the total transaction value could be more than $1 billion. Lumara has a product that helps with the reduction of risks of premature birth. The product, Makena, fetched $130 million in sales for the 12-month duration ending August 31. Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) rose to a new 52-week high of $29.84 on the back of the news.

About the Author

John is a special projects and general assignment reporter, noted for breaking several exclusive stories.

Leave A Response